Welcome to our dedicated page for Roger news (Ticker: ROG), a resource for investors and traders seeking the latest updates and insights on Roger stock.
Overview of Rogers Corporation
Rogers Corporation (ROG) is a globally recognized provider of engineered materials, advanced electronics, and elastomer solutions that power, protect, and connect industries across the world. With a reputation for mission-critical reliability and market-focused innovation, the company serves as a trusted partner for numerous original equipment manufacturers and technology innovators. Leveraging decades of industry expertise, Rogers Corporation has established itself as a key player in the supply chain of high-performance materials essential for clean energy, robust internet connectivity, and safety-driven applications.
Business Segments and Core Offerings
Rogers Corporation operates across three distinct yet complementary business segments, each designed to meet the evolving needs of its diverse customer base:
- Advanced Electronics Solutions: This segment specializes in manufacturing high-quality circuit materials used in communications infrastructure, automotive electronics, and consumer devices. The company’s products are engineered to enhance performance and reliability, bridging the gap between innovative design and industrial durability. Industry keywords such as engineered materials and advanced electronics are deeply embedded in these solutions.
- Elastomeric Material Solutions: Focused on applications that demand superior cushioning, sealing, and impact protection, this segment provides critical components for automotive, transportation, and construction industries. By offering tailored elastomer solutions, Rogers Corporation addresses the essential requirements for safety and performance in environments where shock absorption and durability are critical.
- Other Industrial Solutions: In addition to its core segments, Rogers Corporation delivers elastomer components and specialized materials for a variety of industrial markets. These include product lines that incorporate cushioning and sealing innovations applicable to general industrial equipment as well as unique applications like elastomer floats for level sensing in fuel tanks, motors, and similar settings.
Manufacturing Excellence and Global Footprint
With manufacturing facilities strategically located in multiple countries, Rogers Corporation combines global reach with local expertise. The company employs rigorous quality control and lean manufacturing techniques that ensure each product meets strict operational standards. This global manufacturing footprint supports timely delivery and consistent product quality across diverse markets, reinforcing the company’s commitment to mission-critical reliability.
Commitment to Innovation and Industry Leadership
Innovation is at the core of Rogers Corporation’s strategy. The company continuously invests in research and development to create state-of-the-art solutions that address emerging industry trends. Whether it is enhancing communication infrastructure or improving the safety and efficiency of automotive and industrial systems, Rogers Corporation harnesses innovative technology to solve complex engineering challenges. This dedication not only transforms product performance but also empowers their customers to achieve success in competitive markets.
Market Position and Competitive Landscape
Positioned as a dependable partner for OEMs and component suppliers worldwide, Rogers Corporation stands out due to its unwavering focus on safety, high-quality performance, and strategic market positioning. Its comprehensive product portfolio and expertise in engineered materials allow it to address a vast range of industrial challenges. Despite operating in competitive environments, the company’s emphasis on innovation and reliable product performance reinforces its authority in the industry.
Customer Collaboration and Value Proposition
Rogers Corporation is renowned for building lasting partnerships by delivering exceptional value through its high-performance products. The company works closely with its customers to tailor solutions that meet specific operational needs, thereby ensuring enhanced reliability and superior operational outcomes. These customer-centric practices further solidify Rogers Corporation’s reputation for excellence and reliability.
Summary
In summary, Rogers Corporation’s steadfast commitment to engineering excellence, combined with its diverse product segments and global manufacturing capabilities, underscores its vital role in powering and protecting critical infrastructures. Investors and industry watchers can appreciate the depth of its expertise, its clear focus on operational reliability, and its strategic market positioning that together define the company as a cornerstone in the industrial technology landscape.
Rogers (NYSE:ROG) reported Q4 2024 financial results with net sales of $192.2 million, representing an 8.6% decrease from the previous quarter. The decline was attributed to lower sales in both AES and EMS business units, particularly in wireless infrastructure and industrial sectors.
Gross margin decreased to 32.1% from 35.2% in the prior quarter due to lower volume and unfavorable product mix. GAAP operating margin fell to -2.6% from 6.9%, while adjusted operating margin decreased by 700 basis points to 4.7%. The company reported GAAP earnings per diluted share of $(0.03) compared to $0.58 in the previous quarter, and adjusted earnings of $0.46 per diluted share versus $0.98.
The company ended the quarter with $159.8 million in cash and cash equivalents, an increase of $13.4 million. Net cash provided by operating activities was $33.7 million, with capital expenditures of $15.4 million.
Rogers (NYSE:ROG) has announced it will release its fourth quarter and full year 2024 financial results on February 19, 2025, after market close. The company will host a conference call at 5:00 pm ET on the same day.
The earnings call will be led by Colin Gouveia, President and CEO, alongside Laura Russell, Senior VP and CFO. Investors can access the live webcast and related presentation materials through Rogers' Investor Relations website, where a replay will also be available.
Rogers is a global leader in engineered materials, specializing in solutions for EV/HEV, automotive safety, radar systems, mobile devices, renewable energy, wireless infrastructure, and industrial equipment.
Roche (RHHBY) has received FDA 510(k) clearance for its VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail, a groundbreaking test for diagnosing B-cell lymphoma. This follows its CE Mark approval in June 2024. The test is the first clinically approved in-situ hybridisation (ISH) test capable of assessing all B-cell lymphoma subtypes.
The highly-sensitive test helps distinguish between B-cell cancer and normal immune responses, enabling faster diagnosis and treatment initiation. It can evaluate over 60 B-cell lymphoma subtypes and plasma cell neoplasms on a single tissue slide, working with small biopsies and formalin-fixed tissue. This reduces the need for fresh tissue samples and additional biopsies.
B-cell lymphoma represents about 85% of non-Hodgkin lymphoma (NHL) cases, with NHL being one of the most common cancers in the US, accounting for 4% of all cancer cases and causing over 80,000 deaths annually.
Rogers (NYSE: ROG) has announced the appointment of Woon Keat Moh as an independent member of its Board of Directors, effective January 1, 2025. This addition will expand the Board to nine members, with eight being independent directors. Moh brings nearly 30 years of experience in the specialty materials industry, including significant leadership roles in both Asia and North America. Board Chair Peter Wallace emphasized that Moh's extensive experience in leading global businesses will contribute to Rogers' strategy and shareholder value creation.
Rogers (NYSE: ROG) has appointed Laura Russell as Senior Vice President, Chief Financial Officer and Treasurer, effective December 10. Russell, 49, has been serving as interim CFO since August 2024, following her initial role as Vice President of Finance which she assumed upon joining the company in September 2023.
Prior to Rogers, Russell held key positions including Vice President of Finance, Operations at Wolfspeed (2021-2023) and Vice President of Finance for NXP Semiconductors' Radio Products business (2015-2021). She also worked at Motorola and Freescale Semiconductors from 1997 to 2015. Russell holds a BA in Business Economics from the University of the West of Scotland and is a member of the Chartered Institute of Management Accountants.
Roche has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry companion diagnostic test in Europe for identifying epithelial ovarian cancer patients eligible for ELAHERE treatment. The test detects folate receptor 1 protein, expressed in about 90% of ovarian carcinomas. This certification follows an early exemption approval in Germany and Austria earlier this year. The test aims to enable more precise treatment decisions for ovarian cancer, which causes 46,232 deaths annually in Europe and is the eighth leading cause of cancer death in women worldwide.
Rogers (NYSE:ROG) reported mixed Q3 2024 results with net sales of $210.3 million, down 1.8% from Q2. Despite lower sales, earnings exceeded guidance due to operational improvements and expense management. GAAP operating margin improved to 6.9% from 5.3%, while adjusted earnings reached $0.98 per diluted share. The company faced softer EV/HEV demand and lower seasonal peak in portable electronics. Looking ahead, Q4 sales are expected to decline due to seasonality and customer inventory management. The company highlighted its expansion with a new power substrate factory in China targeting EV/HEV, renewable energy, and industrial markets.
Roche has received FDA approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first companion diagnostic to identify patients with gastric and gastroesophageal junction (GEJ) cancer eligible for targeted treatment with VYLOY. This immunohistochemistry (IHC) assay helps determine CLDN18 protein expression in tumors, enabling clinicians to identify patients who may benefit from Astellas' targeted therapy VYLOY (zolbetuximab).
The assay addresses an unmet medical need by helping predict the likelihood of response to targeted therapy in gastric and GEJ cancers. CLDN18.2 is an emerging biomarker in these cancers. This approval aligns with current guidelines recommending biomarker use to guide therapeutic decision-making in gastric/GEJ cancer.
Gastric cancer is the fifth most common cancer and fourth leading cause of cancer deaths worldwide. In the U.S., 62% of gastric/GEJ cancer cases are advanced at initial diagnosis, with a five-year overall survival rate of only 6%.
Rogers (NYSE:ROG) has announced its plans to release third quarter 2024 financial results on October 24, 2024, after market close. The announcement will be followed by a conference call at 5:00 pm ET, hosted by Colin Gouveia, President and CEO, along with Laura Russell, Interim CFO.
Investors and interested parties can access a live webcast of the event and related slide presentation on Rogers' Investor Relations website. A replay of the event will also be available on the same platform. Rogers is a global leader in engineered materials, specializing in solutions for various industries including automotive, renewable energy, and wireless infrastructure.
Roche's commissioned survey reveals significant gaps in public understanding of HPV and cervical cancer across 12 countries in Latin America and Europe. Key findings include:
- Half of respondents have or no awareness of HPV's role in cervical cancer
- Barriers to screening include fear of pain and discomfort discussing sexual history
- Over 70% of respondents are interested in self-collection options for screening
The survey highlights the need for improved education and accessible screening methods. Roche emphasizes the importance of early detection and prevention, aligning with WHO's goal to eliminate cervical cancer globally. The company has joined the Global HPV Consortium and partners with health systems in over 55 countries to support cervical cancer screening programs using the cobas® HPV test.
FAQ
What is the current stock price of Roger (ROG)?
What is the market cap of Roger (ROG)?
What are the primary business segments of Rogers Corporation?
How does Rogers Corporation differentiate itself in the market?
Who are the typical customers of Rogers Corporation?
What role does research and development play at Rogers Corporation?
How does Rogers Corporation maintain product quality and reliability?
How does Rogers Corporation contribute to the industrial technology sector?
